Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis.

ABSTRACT:

Aims

This meta-analysis investigated the dose-response relationship between circulating galectin-3 levels and adverse outcomes in patients with heart failure (HF).

Methods and results

PubMed and Embase were screened for studies on galectin-3 and HF. The outcomes of interest were all-cause mortality (ACM), and all-cause mortality or HF-related rehospitalization (ACM/HFR), with a follow-up time of more than 6 months. For categorical variables, comparisons between groups with the highest and lowest galectin-3 levels were pooled. For continuous variables, the risks of ACM and ACM/HFR increase per 1-standard deviation (SD) and 1-unit after logarithmic transformation galectin-3 levels were pooled. A random-effects model was employed to calculate the pooled results, and all pooled

SUBMITTER: Cheng W 

PROVIDER: S-EPMC11424282 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature